Insilico Medicine announced a strategic collaboration with Takeda to utilize its proprietary end-to-end platform, Pharma.AI, for advancing drug candidates across Takeda's therapeutic areas. The partnership aims to identify clinically differentiated drug candidates for promising therapeutic targets by using advanced generative models from the earliest stages of design. This collaboration is designed to improve the quality of candidate molecules and optimize them to achieve best-in-class efficacy and safety criteria.

Under the agreement, Insilico will lead AI-driven discovery to identify molecules meeting predefined scientific and early development criteria, while Takeda will apply its global development capabilities to advance selected candidates through clinical validation. The agreement grants Takeda exclusive worldwide rights to develop, manufacture, and commercialize novel therapeutics selected through the collaboration.

"I am excited to partner with one of the top leaders in the biopharmaceutical industry with massive competence in generative AI," said Alex Zhavoronkov, Ph.D., founder, CEO and CBO of Insilico Medicine. "As we deepen the integration of generative AI into every stage of the pharma value chain, I believe the future of pharmaceutical superintelligence has the potential to deliver the highest quality and differentiated drugs. This is a fundamental step on our journey toward extension of healthy productive life."

"By combining Takeda's deep disease biology expertise with Insilico's AI-enabled discovery capabilities, this collaboration seeks to deliver meaningful treatment options for patients by identifying clinically differentiated therapies," said Chris Arendt, Ph.D., Chief Scientific Officer and Head of Research at Takeda. "The partnership also supports Takeda's transition to an AI-native discovery model, as we integrate automation, robotics, and generative AI to advance high-quality candidates more efficiently."

Financial Terms

The financial structure of the agreement includes immediate and future payments based on project milestones and success. Insilico stands to receive significant compensation if the collaboration meets its scientific and commercial objectives.

Insilico Medicine is a clinical-stage generative AI drug discovery company listed on the Main Board of the Hong Kong Stock Exchange under the stock code 03696.HK. Takeda is a values-based, R&D-driven biopharmaceutical company headquartered in Japan.

Insilico Medicine and SK Biopharmaceuticals have entered a research and development collaboration worth up to $2.5 billion to discover AI-enabled drug candidates for neuroimmune disorders of the central nervous system (CNS). Announced at the BIO 2026 International Convention, the partnership aims to address significant unmet patient needs in neuroinflammatory, neurodegenerative, and rare neurological disorders. The total potential deal value represents a record for Insilico with partners in the Asia-Pacific region.

Under the agreement, Insilico will apply its proprietary Pharma.AI platform, spanning target validation, generative chemistry, and molecule optimization, to identify and design novel candidates. SK Biopharmaceuticals will contribute its development and clinical capabilities in neuroimmune disorders, managing late-stage development and commercialization. Financially, Insilico is eligible to receive up to $18 million in upfront and near-term milestone payments. The deal structure includes development, regulatory, and commercial milestone payments, as well as single-digit royalties on net sales upon commercialization.

The collaboration combines Insilico's AI-driven target-to-candidate engine with SK Biopharmaceuticals' CNS expertise. SK Biopharmaceuticals President and CEO Donghoon Lee highlighted the partnership as a scalable growth platform to expand beyond epilepsy. Insilico founder, co-CEO, and CBO Dr. Alex Zhavoronkov emphasized the potential to unlock breakthrough therapies using both traditional small molecules and advanced new modalities.

Insilico's platform has reduced the traditional early-stage drug discovery timeline of 2.5 to 4 years to an average of 12 to 18 months for preclinical candidate nomination. Since 2021, the company has nominated 31 preclinical candidates, 13 of which have received Investigational New Drug (IND) approval or clearance. Insilico is also enhancing its AI platform through MMAI Gym, a benchmarking tool for scientific AI that has attracted partners like Human Longevity and Liquid AI.

Key Financial Terms

SK Biopharmaceuticals, known for commercializing the epilepsy treatment XCOPRI (cenobamate), is leveraging AI to expand its pipeline into radiopharmaceutical therapies and targeted protein degradation. Insilico Medicine, listed on the Hong Kong Stock Exchange under the code 03696.HK, focuses on integrating AI and automation to accelerate drug discovery across fibrosis, oncology, and immunology.